Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Conclusions
We did not find evidence for an increased risk of cardiovascular outcomes with tofacitinib in patients with RA treated in the real-world setting; however, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
Trial registration number
NCT04772248.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Khosrow-Khavar, F., Kim, S. C., Lee, H., Lee, S. B., Desai, R. J. Tags: ARD, Rheumatoid arthritis Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Databases & Libraries | Heart | Heart Attack | Medicare | Rheumatoid Arthritis | Rheumatology | Statistics | Stroke | Study